Dose Insider / Analyses / Wegovy weight loss chart

Wegovy Weight Loss ChartThe Trial Results Week by Week, in Your Own Weight

Updated November 20, 2026 · 23 min read · FDA label, STEP trials

In the main Wegovy trial, people lost 14.9% of their weight on average by week 68, against 2.4% on placebo. The curve ran through about 6% at week 12, 10% at week 20 and 15% at one year, and then flattened. Thirty in 100 people lost a fifth of their weight or more.

14.9%average loss by week 68 in the main Wegovy trial, 2.4% on placebo
Average weight lost on WegovyMain trial, share of starting weightWeek 4−2.3%Week 28−11.7%Week 52−15.5%Week 68−14.9%Placebo, week 68−2.4%Average weight lost onWegovyMain trial, share of starting weightWeek 4−2.3%Week 28−11.7%Week 52−15.5%Week 68−14.9%Placebo, week 68−2.4%

Two thirds of participants lost at least 10% of their weight.

On this page

This page puts that curve into your own weight, week by week. Then it goes through how the dose steps line up with it, how fast the loss runs in each month, how many people reached each threshold, and how the results differ with type 2 diabetes, with the tablets, with the 7.2 mg dose and after two years.

What does the Wegovy curve look like in my weight?

Enter your weight before the first dose and move the slider to any week. If you are already on Wegovy, add your weight now and the calculator compares you with the trial average for that week.

Your Wegovy curveFDA label
Unit
Average—
Lost by then—

Log your weight each week in the app and it draws your own line on this curve.

Open the app

The numbers along the bottom are weeks of treatment, and the scale on the left is percent of starting weight. The curve is the average for people on Wegovy 2.4 mg in the main trial, read from the figure in the label. It is a trial average, not a forecast for one person.

The calculator opens at 232 lb, the average starting weight in the trial, and at week 20, the first month on the full dose. By then the average participant had lost 9.5% of their weight, 22 lb, and weighed 210 lb.

WeekDose at the fastest pace mgAverage lossFrom 232 lb lb
40.252.3%227
80.54.0%223
1215.9%218
161.77.7%214
202.49.5%210
282.411.7%205
362.413.4%201
442.414.7%198
522.415.5%196
602.415.9%195
682.415.7%196

Wegovy label, figure for the main trial, read from the chart. The dose column follows Table 1 of the label.

The trial behind the curve enrolled 1,961 adults with obesity, or with overweight and a weight-related condition, and without diabetes. Two thirds were assigned to Wegovy and one third to placebo, for 68 weeks. The average age was 46, and 74% were women. Everyone in both groups was counselled on a diet with a deficit of about 500 calories a day and on at least 150 minutes of physical activity a week.1

Why the curve ends at 15.7% and the headline says 14.9%

The two numbers answer slightly different questions. The label's table reports 14.9% for everyone who was assigned to Wegovy, including people who stopped the drug along the way, with missing weights filled in by statistical methods. At week 68 the weight was missing for 7.2% of the Wegovy group. The curve in the label's figure, which this page reads week by week, ends a little lower on the page, at 15.7%. The table is the more conservative figure, and it is the one to quote for the trial as a whole.

The same curve for other starting weights

Weight beforeWeek 12 lbWeek 20 lbWeek 36 lbWeek 52 lbWeek 68 lb
200 lb188181173169169
250 lb235226217211211
300 lb282272260254253

Our arithmetic from the curve: 5.9%, 9.5%, 13.4%, 15.5% and 15.7%.

In kilogramsWeek 12 kgWeek 20 kgWeek 36 kgWeek 52 kgWeek 68 kg
From 90 kg84.781.577.976.175.9
From 105 kg98.895.090.988.788.5
From 120 kg112.9108.6103.9101.4101.2

The same arithmetic in kilograms. The trial's average starting weight was 105.4 kg.

When the average passed each mark

The trial average on the curve
Passed 5% of starting weightabout week 10
Passed 10%about week 22
Passed 15%about week 47

The first 5% took ten weeks, the second 5% twelve, and the third twenty-five. That is the slowing pace of the curve in three numbers. The 5% mark, the level usually treated as a clinically meaningful loss, came while the dose was still 1 mg.

Three examples

Week 12, started at 260 lb, now 247 lb. A loss of 13 lb is 5.0%. The trial average at week 12 was 5.9%, so this person is 0.9 points behind, which is about 2 lb.

Week 28, started at 205 lb, now 178 lb. A loss of 27 lb is 13.2%. The average at week 28 was 11.7%, so this person is 1.5 points ahead.

Week 52, started at 300 lb, now 262 lb. A loss of 38 lb is 12.7%. The average at week 52 was 15.5%, so this person is 2.8 points behind, and still inside the two thirds of participants who lost at least 10%.

How do the dose steps line up with the weight loss?

Wegovy starts low and climbs. The label's schedule is four weeks on each of four starter doses, and the full dose from week 17.1

WeeksDose mgShare of the full doseAverage loss by the end of the stepLost during the step
1 to 40.2510%2.3%2.3 points
5 to 80.521%4.0%1.7 points
9 to 12142%5.9%1.9 points
13 to 161.771%7.7%1.8 points
17 to 202.4100%9.5%1.8 points

Schedule from Table 1 of the label. Losses from the label's figure. The third column is our division by 2.4 mg.

The surprise in this table is how even the loss is. The first dose is a tenth of the full dose, and the average participant still lost 2.3% in those four weeks. Each later step, at two, four and seven times the starting dose, took off about the same amount again: 1.7 to 1.9 points. The loss did not wait for the full dose. Half of what the trial average would ever lose was already gone by week 16, before the first 2.4 mg injection.

The label gives the purpose of the slow climb: the escalation is there "to reduce the risk of gastrointestinal adverse reactions". It also allows the climb to be slowed: if a dose is not tolerated, "consider delaying dosage escalation for 4 weeks".1 A person on a slower schedule reaches each row of the table later, so their own line sits above the trial curve in the early months without anything being wrong.

Staying on 1.7 mg

The full dose is not the only maintenance dose. The label says: "The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended)".1 One trial in the label, in 401 East Asian adults, assigned people to one or the other.

At week 68PlaceboWegovy 1.7 mgWegovy 2.4 mg
Average loss2.1%9.6%13.2%
Lost at least 5%19.4%72.8%84%
Lost at least 10%4.5%39.1%59.9%
Lost at least 15%2.6%20.8%38.2%

Wegovy label, Table 10, Study 6. A quarter of the participants had type 2 diabetes.

The 1.7 mg dose gave about three quarters of the loss of 2.4 mg, 9.6% against 13.2%. A person who settles on 1.7 mg for tolerability should expect a curve of the same shape that levels off higher. In the label's large heart trial, of the people still on treatment after a year, 76% were on 2.4 mg, 8% on 1.7 mg and 16% on lower doses, so settling below the full dose is not rare.

How fast is the loss, month by month?

Fastest at the beginning, and slower with every quarter. The curve gives the average pace for each stretch.

StretchLost in the stretchPer 4 weeksPer week, from 232 lb
Weeks 1 to 209.5 points1.9 points1.1 lb
Weeks 21 to 363.9 points1.0 point0.6 lb
Weeks 37 to 522.1 points0.5 points0.3 lb
Weeks 53 to 680.2 pointsunder 0.1 pointsunder 0.1 lb

Our arithmetic from the curve. Points are percent of starting weight.

In the first 20 weeks the average was about 2 points of starting weight every four weeks, a little over a pound a week for someone who began at 232 lb. From week 21 to week 36 the pace halved, and from week 37 to week 52 it halved again. In the last 16 weeks of the trial the average barely moved.

So about 60% of the total loss came in the first 20 weeks, while the dose was still being raised, and about 85% by week 36. A person who compares month five with month one and sees a slower scale is seeing the curve, not a failure of the drug.

How many people reach 5%, 10%, 15% or 20%?

An average hides the spread, and the spread on Wegovy is wide. The label counts how many people in each trial reached each threshold by week 68.1

Who reached the markLabel Table 8
People
Lost at least

Each dot is one person in a hundred on Wegovy 2.4 mg at week 68, counting everyone assigned to the drug.

Lost at leastWegovy, no diabetesPlaceboWegovy, type 2 diabetesPlacebo
5%83.5%31.1%67.4%30.2%
10%66.1%12%44.5%10.2%
15%47.9%4.8%25.1%4.3%
20%30.2%1.7%12.8%2.3%

Wegovy label, Table 8, Studies 2 and 3, week 68.

Among people without diabetes, five in six lost at least 5%, two in three at least 10%, nearly half at least 15%, and three in ten at least 20%. Read from the other side: one person in six did not reach 5%, and one in three did not reach 10%.

The placebo column deserves a look as well. Almost a third of the people on placebo injections lost 5% or more. They had the same diet and activity counselling as everyone else, and for some that was enough. The drug's own contribution is the gap between the columns: 52 more people in 100 reaching 5%, and 54 more reaching 10%.

In pounds, for a 232 lb start, the thresholds are 12, 23, 35 and 46 lb. Three people in ten on Wegovy lost 46 lb or more. Fewer than two in a hundred did so on placebo.

The other trials, mark by mark

Lost at leastWith intensive lifestyle therapyIts placeboTablets 25 mgIts placebo
5%84.8%47.8%76.3%31.3%
10%73%27.1%59.8%14.4%
15%53.4%13.2%47%5.5%
20%33.9%3.5%——

Wegovy label, Tables 8 and 11. Week 68 for the injection, week 64 for the tablets.

The share reaching each mark is much the same across the trials in people without diabetes: around five in six for 5%, around two in three for 10%, around half for 15%. With intensive lifestyle therapy the placebo group did far better, with almost half reaching 5%, which shows how much a structured diet programme can do without the drug.

Does it depend on age or sex?

The label says not: "A reduction in body weight was observed with WEGOVY irrespective of age, sex, race, ethnicity, BMI at baseline, body weight (kg) at baseline, and level of renal function impairment."1 The one feature that clearly changes the average is type 2 diabetes, covered below.

How do the results differ between trials?

The 14.9% comes from one trial in one group of people. The label reports several others: people with type 2 diabetes, people who also had intensive lifestyle therapy, the tablet form, the higher 7.2 mg dose, and a two-year study has been published separately.

Trial by trialLabel, STEP 5
Group

Average loss as a percent of starting weight, everyone assigned. Trials differ in length and in who took part, so the rows are not a ranking of doses.

TrialWhoLength weeksWegovyPlacebo
Main trial, injection 2.4 mgobesity or overweight, no diabetes6814.9%2.4%
Diabetes trial, injection 2.4 mgtype 2 diabetes689.6%3.4%
Intensive lifestyle trial, injection 2.4 mgno diabetes, with a low-calorie diet programme6816.0%5.7%
Tablet trial, 25 mg a dayobesity or overweight, no diabetes6413.6%2.4%
High-dose trial, injection 7.2 mgobesity, no diabetes7218.8%3.9%
Two-year trial, injection 2.4 mgobesity or overweight, no diabetes10415.2%2.6%

Wegovy label, Tables 8, 11 and 12, and Garvey and colleagues, Nature Medicine 2022.

With type 2 diabetes

People with type 2 diabetes lost less: 9.6% on average, against 3.4% on placebo. A quarter of them reached 15%, where nearly half did without diabetes. The same pattern, smaller losses with diabetes, shows in the high-dose trial, where 2.4 mg gave 10.4% in people with diabetes and 15.5% in people without. Someone with diabetes who holds their own line against the main curve on this page is comparing with the wrong group, and the calculator's average will run ahead of them.

With an intensive diet programme

In one trial everyone began with eight weeks on a low-calorie diet of 1,000 to 1,200 calories a day, followed by 60 weeks of a reduced-calorie diet and an activity target rising from 100 to 200 minutes a week. With that much support, the placebo group lost 5.7%, more than twice what placebo groups lost elsewhere. The Wegovy group lost 16.0%, about one point more than in the main trial.1 The intensive programme raised the floor for everyone and added little on top of the drug.

The tablets

Wegovy also comes as a 25 mg tablet taken once a day. In its trial the average loss was 13.6% at week 64, against 2.4% on placebo, and 76 in 100 people lost at least 5%. The tablet is stepped up over 12 weeks, in three 30-day steps of 1.5, 4 and 9 mg, before the 25 mg dose.1 The curve on this page is for the injection, and the tablet trial was a few weeks shorter, so the two should be compared loosely.

The 7.2 mg dose

Since 2026 the label includes a higher injection dose, 7.2 mg, for people who have been on 2.4 mg for at least 4 weeks. Its trial compared three groups for 72 weeks.

Average loss at week 72 in the high-dose trial
Wegovy 7.2 mg18.8%
Wegovy 2.4 mg15.5%
Placebo3.9%

The higher dose added 3.3 points over 2.4 mg. It also added side effects. In the label's table for that trial, nausea was reported by 39 in 100 people on 7.2 mg and 35 on 2.4 mg, vomiting by 22 and 16, and an altered skin sensation by 22 and 6.1

Teenagers

Wegovy is approved from age 12, and the label reports a 68-week trial in 201 teenagers with obesity. For growing bodies the measure is BMI, not weight. The average BMI fell by 16.1% on Wegovy and rose by 0.6% on placebo, and 77 in 100 teenagers on Wegovy lowered their BMI by at least 5%, against 20 in 100 on placebo.1 The curve on this page is from adults and should not be applied to a teenager.

After two years

A separate trial, STEP 5, kept 304 people on Wegovy 2.4 mg or placebo for 104 weeks. The average loss at two years was 15.2% on Wegovy and 2.6% on placebo, and 77.1% of the Wegovy group were still at least 5% down, against 34.4% on placebo.2 The two-year figure is almost the same as the one-year figure in the main trial. The weight reached in the first year was the weight held in the second.

Two years also give the longest view of tolerability. Stomach and bowel side effects, mostly mild to moderate, were reported at some point by 82.2% of the Wegovy group and 53.9% of the placebo group, and 92.8% of all participants completed the trial.2

What the placebo groups show

Every trial on this page had a placebo group that received the same counselling on diet and activity. Their average losses give a measure of what that counselling does without the drug: 2.4% in the main trial, 2.6% over two years, 3.4% in people with diabetes, and 5.7% where the programme began with eight weeks on a low-calorie diet. Against those figures the drug added 10 to 15 points in people without diabetes.

When does the weight level off?

Around the end of the first year. On the curve, the average was 15.5% down at week 52, 15.9% at week 60 and 15.7% at week 68. The lowest point was at week 60, and after week 52 nothing moved by more than half a point.

The two-year trial confirms that this is a level and not a pause. Its 15.2% at week 104 sits inside the same narrow band. On continued treatment the average neither kept falling nor crept back.

For one person the timing will differ. The pattern to expect is the one in the pace table: quick loss over the first five months, a slower second half of the year, and then a weight that holds as long as the injections continue.

What side effects come along the curve?

Mostly stomach and bowel effects, and mostly in the same months in which the weight falls fastest. The label's table for the main trials gives how many people reported each one at any time.1

People per 100Wegovy 2.4 mgPlaceboA typical episode lasted days
Nausea44168
Diarrhea30163
Vomiting2462
Constipation241147

Wegovy label, Table 3, and Wharton and colleagues, Diabetes, Obesity and Metabolism 2022, for the median length of an episode.

An analysis of the same trials followed these effects through time. The share of people with nausea, vomiting or diarrhea at any one moment "peaked at about week 20 and decreased thereafter", and constipation levelled off at about week 10.7 Week 20 is the first month on the full dose, the same point at which the weight curve begins to slow. The side effects and the fast part of the loss belong to the same stretch.

Few people gave up over them. In the label, 6.8% of people on Wegovy stopped treatment because of side effects, against 3.2% on placebo. Nausea was the most common reason, at 1.8%. In the analysis, stomach and bowel effects led to a lower dose or a pause in 12.5% of people, and 98.1% of the events were rated mild or moderate.

Side effects did not explain the weight loss. People without any stomach side effects lost about as much as people with them, and the analysis estimated that less than 1 percentage point of the extra loss on Wegovy ran through those effects.7

What happens to the curve if I stop?

It turns upward. Two Wegovy trials tested this. In one, people who had taken Wegovy for 20 weeks were switched to placebo: over the next 48 weeks they gained 6.9% of their weight, while those who continued lost a further 7.9%.4 In the other, people who stopped after the full 68 weeks, having lost 17.3%, were followed for a year: they regained 11.6 percentage points and ended 5.6% below their starting weight.3

Stopped afterLoss by thenA year or so later
20 weeks10.6%gained 6.9% of their weight in 48 weeks
68 weeks17.3%regained 11.6 points, ending 5.6% below the start

Rubino and colleagues 2021 and Wilding and colleagues 2022.

The Wegovy label makes the same point about one of these trials in a single line: the people in it had all tolerated the full dose before being assigned, so its results "may not reflect the experience of patients in the general population who are first starting". The article on what happens after stopping covers the regain trials for both drugs.

How does the Wegovy curve compare with Zepbound?

Zepbound's curve runs lower. In each drug's own main trial, the average loss was 14.9% on Wegovy at week 68 and 15.0%, 19.5% and 20.9% on Zepbound 5, 10 and 15 mg at week 72.6 In the one trial that assigned people to one drug or the other, the average at week 72 was 13.7% on semaglutide and 20.2% on tirzepatide.5

WeekWegovy 2.4 mgZepbound 5 mgZepbound 10 mgZepbound 15 mg
125.9%7.9%8.6%8.6%
209.5%10.4%12.6%12.6%
3613.4%13.7%17.4%18.1%
52 for Wegovy, 48 for Zepbound15.5%15.0%19.1%20.2%
68 for Wegovy, 72 for Zepbound15.7%16.1%20.9%22.0%

Figures in the two labels for each drug's main trial, read from the charts. Separate trials, so the columns are a rough guide.

Wegovy 2.4 mg and Zepbound 5 mg track each other closely from week 36 on. The higher Zepbound doses pull away from week 12. The Zepbound weight loss chart has that curve in your own weight, and the head-to-head comparison covers the direct trial.

How much of the loss is fat?

About three fifths, in the body scans done in the main trial. In 140 participants who were scanned at the start and at week 68, fat mass fell by 19.3% on Wegovy and lean mass by 9.7%. A 2025 advisory from four medical societies gives the split in kilograms: of an average 13.6 kg lost, 8.3 kg was fat and 5.3 kg was lean tissue, which it puts at 62% and 38%.89

Lean tissue is not all muscle. The advisory estimates that muscle is about half of it, so about a fifth of the weight lost was muscle. Because fat fell twice as fast as lean tissue, the share of lean tissue in the body went up by 3 percentage points over the trial, even though its amount went down. The article on muscle loss splits your own loss by these figures.

What happens to the waist?

It shrinks along with the weight. In the main trial the average waist went down by 13.5 cm on Wegovy, about 5 inches, and by 4.1 cm on placebo.1 In the trial against Zepbound the semaglutide group lost 13.0 cm, so the figure is consistent across studies.5

Does the weight loss come with fewer heart attacks and strokes?

In people who already had heart disease, yes. The label reports a trial of 17,604 adults with established cardiovascular disease and obesity or overweight, followed for a median of 41.8 months on Wegovy 2.4 mg or placebo.1

Over a median of 41.8 monthsWegovyPlaceboRelative risk
Cardiovascular death, heart attack or stroke6.5%8%20% lower
Heart attack2.8%3.8%28% lower
Death from any cause4.3%5.2%19% lower

Wegovy label, Table 6. The first row is the trial's main result. The label lists the other two among its secondary and other endpoints.

The main result was 569 events among 8,803 people on Wegovy and 701 among 8,801 on placebo. This is why Wegovy carries an approved use that goes beyond weight: lowering the risk of major cardiovascular events in adults with established heart disease and obesity or overweight. The trial enrolled people with heart disease, so it does not show the same benefit for someone without it.

What if I am behind the curve?

Being under the average is the normal position for half of the people on any drug. The threshold table shows how many: by week 68, one person in six on Wegovy had not lost 5%, and one in three had not lost 10%.

Three ordinary reasons put a person's line above the trial curve without anything having gone wrong. The first is a slower dose schedule: the label allows each step to be delayed by 4 weeks, and every delay shifts the whole curve to the right. The second is diabetes, where the average loss is about two thirds of the figure without it. The third is missed or late doses, which the trial average does not have many of.

Feeling fine is not a reason to worry either. In the analysis of stomach side effects, people who had none lost about as much as people who had them: 9.6% to 17.1% across the trials, against 11.4% to 17.7%.7 An easy ride through the dose steps does not mean the drug is not working.

The useful comparison is with the pace table and not with a single week. A person who is still losing a point a month at week 30 is on the curve's shape, wherever its height. A person whose weight has not moved for three months at week 30, with the full dose and no missed injections, has a question for their prescriber, and since 2026 one of the possible answers is in the label: the 7.2 mg dose.

What do missed doses do to the curve?

The trial curve belongs to people who mostly took their injections. Semaglutide has a half-life of about a week, so one missed dose lowers the level by about half before the next one, and the label has a rule for it: if the next scheduled dose is more than 2 days away, take the missed one as soon as possible; if it is less than 2 days away, skip it.1

A longer break matters more, and here the label is explicit: after 2 or more missed doses in a row, the step-up should be started again "at a lower dosage to reduce the risk of gastrointestinal adverse reactions". A restart sends a person back along the dose table, and their curve with it. The article on missed doses has a checker for any gap.

What can this chart not tell you?

It is an average. The same trial contained people who lost under 5% and people who lost over 20%. The curve is the middle.

The weekly values are read from a chart. The label prints the curve as a figure. The values between the label's stated results are our reading of that figure, to about a tenth of a point.

The schedule in the trial was the fastest one. Sixteen weeks to the full dose. Many people take longer.

Everyone had counselling. The trial's participants were coached on diet and activity throughout. The placebo group's 2.4% shows what that counselling did without the drug.

The maker ran the trials. The STEP trials were run by Novo Nordisk, which sells Wegovy.

Short answers to common questions

How much weight do you lose in the first month on Wegovy?

About 2.3% of starting weight on average, on the 0.25 mg starter dose. For a 232 lb person that is about 5 lb.

How much in three months?

About 5.9% at week 12, or 14 lb from 232 lb. At that point the dose is 1 mg.

How much in six months?

About 11% at week 26, reading between the curve's points at weeks 20 and 28. That is about 26 lb from 232 lb.

How much in a year?

About 15.5% at week 52, or 36 lb from 232 lb. The label's figure for the end of the trial at week 68, counting everyone, is 14.9%.

When does Wegovy start working?

The average curve is already down 2.3% at week 4, on a tenth of the full dose. The full dose is reached at week 17.

Why has my weight loss slowed after five months?

That is the shape of the trial curve. The average pace was about 1.9 points per four weeks up to week 20, 1 point from week 21 to 36, and half a point from week 37 to 52.

Is Wegovy weight loss permanent?

It held for two years in the trial that continued treatment: 15.2% at week 104. In the trials that stopped the drug, most of the weight returned within a year.

How much more does the 7.2 mg dose take off?

In its trial, 18.8% at week 72 against 15.5% on 2.4 mg, a gap of 3.3 points, with more nausea, vomiting and altered skin sensation.

Is 1.7 mg enough?

It is one of the two maintenance doses the label names for adults. In the trial that tested both, the average loss was 9.6% on 1.7 mg and 13.2% on 2.4 mg.

How much of the weight lost on Wegovy is fat?

About 62% in the trial's body scans, with 38% lean tissue, of which about half is muscle.

Do the tablets work as well as the injection?

In their own trial the 25 mg tablets gave an average loss of 13.6% at week 64, against 14.9% at week 68 for the injection in its trial. The two were not compared directly.

Does Wegovy work for teenagers?

In the label's trial in 201 teenagers, average BMI fell by 16.1% on Wegovy and rose by 0.6% on placebo over 68 weeks.

Do men and older people lose less on Wegovy?

The label states that weight reduction was seen irrespective of age and sex. It reports a clearly smaller average only for people with type 2 diabetes: 9.6% against 14.9%.

I have no side effects. Is it working?

Side effects are not the measure. People with no stomach side effects lost 9.6% to 17.1% across the trials, about the same as people who had them.

How the calculator works

The calculator holds the average percent change in body weight at weeks 4, 8, 12, 16, 20, 28, 36, 44, 52, 60 and 68 for people on Wegovy 2.4 mg in the main trial, read from the figure in the label. Between those weeks it draws a straight line. It multiplies the percentage for the week you pick by your starting weight. If you enter your weight now, it works out your own percentage and gives the difference from the average in points. The dose for each week follows the label's fastest schedule.

The dots chart shows the label's shares of people reaching each threshold at week 68, rounded to whole people. The trial chart shows the average loss in each trial as the label and the two-year paper report it.

Sources

  1. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 2.2, 2.3, 6.1 and 14 (Tables 1, 8, 11, 12 and 13). accessdata.fda.gov
  2. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022;28:2083-2091. doi:10.1038/s41591-022-02026-4
  3. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022;24:1553-1564. doi:10.1111/dom.14725
  4. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224
  5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med 2025;393:26-36. doi:10.1056/NEJMoa2416394
  6. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; section 14.1. accessdata.fda.gov
  7. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab 2022;24:94-105. doi:10.1111/dom.14551
  8. Wilding J, Batterham R, Calanna S, et al. Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study. J Endocr Soc 2021;5(Suppl 1):A16-A17. PMC8089287
  9. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336

Related analyses

Log your weight each week and the app draws your line on this curve.

Open Dose Insider